Dr. Sabari on the EVOKE-02 Trial With Sacituzumab Govitecan in NSCLC

Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.

Related Keywords

,Department Of Medicine ,Grossman School Of Medicine ,Langone Health Perlmutter Cancer Center ,Perlmutter Cancer Center ,International Association ,Lung Cancer ,Tulung ,Non Small Cell Lung Cancer ,Nsclc ,Phase 2 Evoke Trial Nct05186974 ,Phase 3 Evoke 03 Trial Nct05609968 ,Pembrolizumab ,Sacituzumab Govitecan Hziy ,